先声药业 Simcere

SIMCERE PHARMACEUTICAL GROUP LIMITED

# 2022 R&D DAY

*STOCK CODE: 2096.HK*

# DISCLAIMER

These presentation materials have been prepared by Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 (the "Company") in accordance with the prevailing economic, legal, market and other conditions and for information only. It should be understood that any subsequent development could affect the information contained in such presentation materials and that the Company, the Company's advisors, their respective advisers or representatives shall not be obliged to make any revision, amendment or acknowledgement to such information. It is information in summary form and does not purport to be complete, not does it constitute a recommendation regarding the securities of the Company (the "Securities").

The information contained in these presentation materials has not been reviewed by any regulatory authorities, and has not been independently verified. The Company does not intend to provide, and you should not rely on these presentation materials to obtain, a complete or comprehensive analysis of the financial or trading position or prospects of the Company. The Company, its shareholders, its advisers, and their respective members, affiliates, directors, supervisors, officers, employees, agents, advisers or representatives shall make no express or implied representation, warranty or undertaking as to the accuracy, reliability, completeness, fairness, reasonableness or correctness of the information contained in these presentation materials, and the Company, its shareholders, its advisers and their respective members, affiliates, directors, supervisors, officers, employees, agents, advisers or representatives disclaim any liability whatsoever arising from directly or indirectly using or relying on such materials. This document contains no information or material which may result in it being deemed (1) to be a prospectus within the meaning of section 2(1) of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), or an advertisement in relation to a prospectus or proposed prospectus or extract from or abridged version of a prospectus within the meaning of section 38B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance or an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being able to invoke any exemption available under the laws of Hong Kong and is subject to material change without notice. These presentation materials contain certain statements which are or may be forward-looking statements. These statements usually contain "will", "anticipate" or "expect" and expressions of similar meanings. These forward-looking statements, given its nature, are subject to risks and uncertainties as such statements involve events which may occur in the future and depend on the conditions, assumptions and factors of such occurrence. These assumptions and factors are based on the information available to the management in relation to the business of the Company or the industry in which it operates, which may be proven false, inaccurate or incomplete. There is no assurance that these expectations shall be correct, accurate or complete. There may also be some other significant risks which have not been identified by the Company as significant risks, while the Company and its advisers or representatives may not be aware of such risks. In light of these uncertainties, no reliance shall be placed upon these forward-looking statements. The Company and its advisors assume no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. By participating in the meeting for this presentation or reading these presentation materials, you acknowledge that you are solely responsible for assessing the business, financial position, operating results, operating and market conditions, or prospects of the Company, and that you will analyze and be solely responsible for your viewpoints as to the future performance of the Company.

These presentation materials have not been filed, lodged or registered with any jurisdiction nor approved by any jurisdiction. The recipients of these presentation materials should understand and observe any applicable legal or regulatory requirements. These presentation materials shall not constitute or form part of any offer or issue of the Securities nor any solicitation or invitation for offer of purchase or subscription of the Securities. These presentation materials are provided to you for information only and shall be kept confidential and shall not be reproduced in whole or in part in any form or distributed in any form to any other person. In particular, it is not permitted to reproduce or disseminate any information appearing in these presentation materials or any copies of these presentation materials, directly or indirectly, to any person in the U.S., Japan, Hong Kong or any other jurisdiction where it shall be unlawful under the laws of such jurisdiction. Any violation of these restrictions may constitute violation of the securities laws of the U.S. or other countries. These presentation materials and any information contained therein shall not constitute any solicitation for money, securities or other considerations, while any money, securities or other considerations provided as a result of these presentation materials and any information contained therein shall not be acceptable to the Company. These presentation materials and the information contained therein shall not constitute any execution of any agreement for purchase, acquisition, disposal, subscription or underwriting of any securities or structured products or any invitation thereof , and no offer or solicitation has been made in respect of the purchase or subscription of any Securities.

The Securities referred to herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act") or any state securities laws of the United States, and may not be offered or sold within the United States except pursuant to an exemption under, or in a transaction not subject to, the registration requirements of the Securities Act. There will be no public offering of the Company's securities in the United States. By reviewing these presentation materials, you are deemed to agree and acknowledge yourself and the client you act on behalf is (a) a "professional investor" under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) or any regulation of such ordinance; (b) a "Qualified Institutional Investor" (as defined in Rule 144A of the United States Securities Act); or (c) a non-U.S. person (as defined in Regulation S under the United States Securities Act) who is outside the United States and not acting for the account or benefits of a U.S. person (as defined in Regulation S under the United States Securities Act).

These presentation materials or any content thereof is not intended to be or constitute provision of consultancy or advisory services of any securities. Save for those mentioned above, distribution of these presentation materials does not constitute a public offer of shares under the securities laws of the PRC, and it is not intended to constitute provision of consultancy or advisory services of securities investment as defined under the laws of the PRC.

# AGENDA

## 01 Welcome Speech

Ren Jingsheng
*Chairman of the Board & CEO*

*5min*

## 02 Company Overview Strategy

Zhou Gaobo
*CIO*

*10min*

## 03 Pre-clinical R&D Update

Tang Renhong, PhD
*EVP*

*20min*

## 04 Late-stage Oncology Pipeline

Bijoyesh Mookerjee , MD
*CMO， Oncology*

*20min*

## 05 Late-stage Non-oncology Pipeline

Danny Chen , PhD
*SVP, neuroscience*

*20min*

## 06 Strengthening BD, M&A and Investments within a Global Strategy

Kevin Oliver , PhD
*SVP, Global Head of BD&L*

*10min*

## 07 Q&A - ALL

HOST : Jason Bao
*Secretary of the Board*

# Company Overview Strategy

Zhou Gaobo
*CIO*

# Fundamentals of our business driven by extensive unmet clinical needs in China and beyond

## Forecast of global patient population in 2030: China, EU, US (10,000 people)




Note:
CNS diseases: AD, Schizophrenia, Dysthymia, Deprementia, BD, Epilepsy, Cerebral Stroke, PD;
Autoimmune diseases: RA, AS, Psoriasis, SLE, Gout, Sjögren's Syndrome, Atopicdermatitis, UC, Vitiligo, Alopecia Areata;

Source: analysis of World Bank and Silicon Valley Bank, data of GD and CCI

# Biopharma innovation flourishing in China while bottlenecks also emerging —— industry entering innovation 2.0 era

## Biopharma innovation driven by growth patient needs, improving healthcare reform policies, and capital infusion

Number of IND applications in China




## Intense competition and crowding limit quality of China's biopharma innovation

Clinical research programs sponsored by domestic biotech and pharmacos in China

TOP 5 targets
**46%**

TOP 10 targets
**64%**



*Note: according to clinical research statistics from IND to Phase III trials*

Source: PHARMACUBE Database

# Simcere is on a journey to build an R&D-driven pharmaceutical company

**2021**

- **Innovative drugs account for more than half of total revenue**
- ENWEIDA ® approved for marketing

**2016-2020**

- Established Shanghai Innovation Center and Boston Innovation Center
- Sanbexin® approved for marketing
- Listed on the Hong Kong Stock Exchange

**2011-2015**

- Iremod® approved for marketing
- Established State Key Laboratory

**2006-2010**

- Launched the company's first innovative drug Endostar®
- Listed on the New York Stock Exchange
- Innovative research capability equipped

# Innovative and competitively differentiated products contribute to 60%+ of Simcere's revenue

## Share of innovative products in total revenue




## Sanbexin®

**The only newly approved stroke drug globally since 2015**

**13** days: NDA approval to commercial delivery

**80** hours: first shipment to country-wide availability

**5** months: NDA approval to NRDL listing

Entered **2,400** hospitals in first year of launch

**100+% growth** annually, major contributor to **CNS portfolio**


## ENWEIDA (Envafolimab)

**Global first subcutaneous PD-L1**

2021.11.25
**Approved**

**2,000** patients treated in the first 30 days


## COSELA (Trilaciclib)

**First-in-class comprehensive myelo-protective therapy**

2021.11.29
**NDA priority review by NMPA**

Expected approval for in China in 2022

# Full value chain capabilities enable Simcere's innovation aspiration

## R&D capabilities

**4** R&D and innovation centers: Shanghai, Nanjing, Beijing, Boston

State Key Laboratory of Translational Medicine and Innovative Drugs

**950** strong R&D organization, including nearly **300** clinical team members

## Differentiated product portfolio

**5** innovative drugs in three core therapeutic areas

**40+** products included in NRDL and Essential drug list

**10+** products included in clinical guidelines

Three core TAs:

**Oncology, CNS, Autoimmune**

with focus on areas of

significant future impact



## Leading commercialization capabilities

**Over 4,000 professional sales staff**

Reaching approximately **3,000** Level A municipal hospitals nationwide

**37,000** other hospitals and medical institutions

**200** national and regional pharmacy chains

## International Standards

**5** GMP manufacturing sites

Various dosage forms of small and large molecules, prokaryotic and eukaryotic protein production capability

Select products exported to US and EU markets

# Accelerating towards innovation through in-house R&D and partner collaboration

## Local innovation capabilities

### Innovation Center Shanghai

Oncology & Immunology
Pre-/clinical capability

### Innovation Center Beijing

Neuroscience & Transl Sci
Clinical Dev, Registration, IP

### National Key Lab Nanjing

Translational Medicine
Innovation Drug

### Innovation Center Boston

- Global clinical Development
- BD Development
- New opportunity with breakthrough potentials

## Track record as partner of choice

| 2021.3 | 2021.6 | 2021.11 | 2021.12 | 2022.3 |
|---|---|---|---|---|
| KAZIA THERAPEUTICS | vivoryon | 中国科学院上海药物研究所 SIMM | Avilex pharma | |

# Sustained R&D investment for future growth

R&D Spending Ratio




2021 R&D spending

**1.4 B Yuan**

Year-on-year growth

**24.1%**

R&D Talent Pool




Number of R&D employees

**950 +**

Percentage with advanced degree

**> 60 %**

# Seasoned team with global vision

**Renhong Tang**

Exe Director, VP


**Gaobo Zhou**

CIO

McKinsey&Company

**Kevin Oliver**

SVP, BD&L


**Bijoyesh Mookerjee**

CMO, Oncology


**Danny Chen**

SVP, Neuroscience


**Qin Huang**

SVP

**Mark Coflin**

VP


**Yan Xu**

VP, Clinic

janssen

**Vickki Song**

VP


**Feng Wang**

VP

# Sustained high quality growth driven by key innovative products

## Projected share of innovative products in total revenue




| | | **Peak sales** (USD) |
|---|---|---|
|  | Sanbexin® | **$800 M** |
| 先必新® | Sanbexin Sublingual tablet | **$500 M** |
|  | ENWEIDA® | **$400 M** |
|  | Trilaciclib | **$400 M** |
|  | Sevacizumab | **$250 M** |
|  | Endostar® (New indication) | **$150 M** |
|  | Oral 3CL Inhibitor | – |

# Key developments expected in 2022

**Commercialization**

**Sanbexin®，ENWEIDA®**

Innovative drugs sales continue to ramp-up rapidly

**Expansion of key product**

**Sanbexin sublingual tablet**

China phase III clinical trial to be completed in H1 2022

**New Product Launch**

**Trilaciclib (ES-SCLC)**

First-in-class new drug expect to be launched in China in 2022

**Joining the fight against COVID-19**

**Oral 3CL Inhibitor**

Rapid clinical advancement in China and abroad



# Highlights

| | |
|---|---|
| Trilaciclib | is expected to be launched in China in 2022. Targeting large Chinese patient population receiving chemotherapy, the product has the potential of gaining huge market share and attention. |
| Sanbexin® | achieved annual sales of RMB 1.5 billion in its first year. The rapid clinical development of Sanbaxin sublingual tablets for sequential stroke treatment and other investigational news drugs in piple is forming a multi-mechanism full-course therapeutic approach. |
| SIM0417 | is the first oral 3CL inhibitor approved for clinical trial in China . The first subject enrollment is achieved in early April. |
| Innovation | Simcere has formed a new drug R&D pipeline of nearly 60 projects, with 20 projects in clinical stage, involving 17 potential innovative drugs. |
| Globalization | Simcere is seeking global expansion in diversified strategies of BD licensing, R&D overseas, internationalized organization and talent pool etc. |

# Preclinical Drug R&D

Tang Renhong, PhD
*EVP*

# Preclinical R&D Strategy and Drug Discovery Engines

# Patient-Centric Drug Discovery Strategy

- Fulfilling the clinical needs of patients as the core R&D goals

- Taking lead in competition with technology competence and execution for high-value projects

- Developing a diversified portfolio through both internal R&D and external collaboration

- Delivering value to global patients and stakeholders

# Growing Portfolio with Strong long-term Potential




- Research Delivered 17 Molecules to the Clinical in less than 5 years
- Majority from internal R&D that support by our integrated Discovery and Development platforms

# Proprietary platforms support diversified drug modalities

Proprietary platforms enable us to differentiate Molecule from the initial design

**Hybridoma**



**Phage Display**

**Protein Engineering**

**Single B cell Clone**

**Nanobody**



**Half-life Extension**

**Engineered mice**

**Humanized Models**



**DEL Lib AI&ML**


Diversified therapeutic modality to conquer undruggable targets

**T-Cell Engager**

**ADC**

**NK Engager**

**Bispecific Ab**

**Cytokine fusion**



**PROTAC/ML**

# Simcere Creative platform of Protein Engineering



# Adopting AI in Drug Discovery




- Focus on the application on early-stage drug discovery, such as hit generation and optimization
- Establishing data science infrastructure and capability internally
- Collaborating with external partner for agile development

## Internal Capability

- Molecular Docking
- Virtual Screen
- Dynamics Simulation
- ADMET Prediction
- Free Energy calculation
- DEL Panning

## Collaboration



# Project X - Our Path to the Future

…to attract and unite a group of young talents in life science and focusing on exploring and creating unprecedented treatments through a series of disruptive innovations..


- 10 directions/technologies with either high treatment needs or breakthrough potential
- An ecosystem to connect Academic research and Industry for drug discovery
- fill the gap during the transformation of research hypothesis to therapeutics development
- Building the true innovative research engine

# Diseases-Specific Strategies and key Assets

Oncology, Autoimmunity, Neuroscience

# Oncology

**Building Depth on prioritized tumor types: Lung, Breast, GI, Female reproductive, Hematological malignancy**

## Biologics

- Cell surface checkpoint modulation on cytotoxic immune cells
- Blocking inhibitory effect from suppressive immune cells such as Treg， MDSC
- Cytokine and fusion protein to enhance the effect of current checkpoint modulators
- TAA and neoantigens for Immune cell engagers and ADC
- Promoting antigen presenting， Immune cell infiltration, tumor recognition and phagocytosis
- Involved MoAs: TIGIT/PVRIG, PD-L1-IL15v, SIRPa(mu)-Fc， MSLN-CD3, P95/Her2-ADC

**Immune Cells Function**

**Tumor Cells**

**Tumor Microenvironment**

## Small Mol

- Activation of Innate Immune response
- Blocking T cell exhaustion through intracellular checkpoint modulation
- Cell Cycle Modulation to address treatment resistance
- Synthetic lethal at varies levels， DNA repairing, metabolism, transcription
- Critical Signal protein modulation and degradation
- Involved Targets: RAD51, MAT2a， CDK2/4/6, USP1, CBL-b

# SIM0348: TIGIT/PVRIG Bispecific Antibody

**Dual Checkpoint targeting for enhanced T cells stimulation**

## Strong T and NK Cell Activation and Treg Killing




## Great Monotherapy efficacy with tumor regression

A375 hPBMC humanized xenograft model




## Significant Synergy Effect With Tecentriq

A375 hPBMC humanized xenograft model




- **Simultaneously targeting two checkpoints for improved immune activation**
- **Engineered Fc part lead to high efficient Treg cells killing**
- **> 50% Tumor growth inhibition achieved in PD-L1 blocker insensitive model**

# SIM0237: PD-L1/IL15v Bifunctional Fusion Protein

**Best-in-Class potential with Improved tumor control and low safety risk**




## Rationale:

- Blocking PD-1/PD-L1 signaling and deliver IL-15 directly to TME for fully activation of CD8 T cells
- Fine tune IL-15 pharmacological profile through protein engineering

## Reduced T/NK Proliferation to Increase Therapy Window




## Significant Tumor Growth Inhibition




NCI-H292-hPBMC xenograft model

# SIM0317: First-in-Class RAD51 inhibitor

**Significant advantages on efficacy, safety , developability compared to current leading competitor**

- RAD51 plays a central role in the homologous recombination pathway
- Overexpressed in several human malignancies, correlates with poor prognosis
- Synthetic lethality with AID overexpressed tumors
- Multiple combination potential with chemotherapy and other DDR pathway-targeting therapeutics

## Superior In Vitro Activity And In Vivo Efficacy







## Broad combination opportunities for multiple tumor types

Combo with Cisplatin in NSCLC




Combo with Docetaxel in Pancreatic Cancer




Combo with ATRi in NSCLC




Combo with WEE1i in TNBC



# SIM0413：First-in-Class Target without chemistry start

- Target plays a pivot role in mismatch repair (MMR) with synthetic lethal potential to microsatellite instability (MSI)
- Current no publicly disclosed inhibitor yet
- Successful identification of Hit compound through virtual lib screening supported by machine learning algorithm
- Compound show potent *in vitro* activity, inducing DNA damage, lead to selective suppression of MSI tumors

**Enzyme Inhibition**




**Induction of DNA Damage**




**Tumor Growth Inhibition**



# Autoimmunity

## Treg Biology

01

- Selectively stimulate Treg cell proliferation or its function
- Re-establish Treg/Teffs balance

## Targeted Delivery of Immunosuppressive agents

02

- Profound immuno-suppression in disease organs
- Minimizing the systemic side-effects

# SIM0278：IL-2 mutein specifically Promote Treg Function

## Differentiation through protein engineering




- improve Thermostability
- Avoid interaction with IL-2Ra
- Lower affinity to IL-2Rβγ
- Iincreased IL-2Rαβγ/IL-2Rβγ window
- Treg-biased binding

### Strong Treg activation extreme low Tcon stimulation







### Great anti-inflammation Prevent GvHD occurrence







### Significant increase of Treg ration in cyno



# Ab-Steroid conjugate for Th2 suppression

## Significant decrease of IgE production and inflammatory cell infiltration bring great histological improvement

### Ear thickness and IgE production




### lymphocyte Infiltration




### Histological Score



# Neuroscience

**Strengthening our core competence in stroke, expand to neurodegenerative Diseases**

## Stroke

- Whole disease course management
- co-morbidities control through new MoA/Modalities
- Hemorrhagic Stroke expansion



## Neurodegenerative Diseases

- Combination of multiple mechanisms for early intervention
- Inhibit neurocytotoxic protein aggregation
- Neuroimmune modulation through targeting microglia cells

# Expand Sanbexin® to Hemorrhagic Stroke

## Collagenase-induced intracerebral hemorrhage Model

### Reduce Cerebral Edema




### Improve Neuron Function




## Subarachnoid Hemorrhage Model

### Protect Blood-Brain Barrier Integrity




### Ameliorate Dyskinesia



# SIM0417: Inhibitor of COVID-19 3CLpro

**Oral 3CL protease inhibitor jointly developed with Shanghai Institute of Materia Medica**

**2021.11.17** — Collaboration with SIMM

**2022.03.28** — IND Approval

**2022.04.10** — Phase 1 FIH

**2022 Q3** — **Phase 2/3 trials**

- **Good Antiviral Activity** great antiviral activity against wild-type, delta and Omicron strain, inhibit viral replication in lung and brain tissue, significantly improve lung damage caused by the virus.
- **Excellent *in vivo* Pharmacokinetic Properties** SIM0417 has good pharmacokinetic properties *in vivo*, its lung tissue exposure is higher than that of competitor molecule, and it has a lower human plasma protein binding ratio.
- **Good Safety Margin** identified by repeated-dose GLP tox, **No** genotoxicity.



# Expected submissions in 2022

## Q1

- ✓ SIM0272 PRMT5 China IND
- ✓ SIM0417 3CL(COVID19) China IND

## Q2

- SIM0323 CD80/IL2v China IND

## Q3

- SIM0237 PD-L1/IL15v US IND
- SIM0348 TIGIT/PVRIG US IND

## Q4

- SIM0237 PD-L1/IL15v China IND
- SIM0419 PSD-95 China IND
- SIM0271 MAT2A China IND
- SIM0348 TIGIT/PVRIG China IND
- SIM0278 IL-2mu-Fc US IND

Oncology | Autoimmunity | Neuroscience

# Key Takeaways for Today

1. Patient-centered principle is core of our drug R&D efforts
2. Build competence in platform technology to create competitive advantages
3. Improve TA-focused strategy through deeper understanding of disease biology
4. Quick and agile execution of high potential assets for clinical validation
5. Establish solid foundation of next-gen innovation through Project X for long-term growth

# Late-stage Oncology Pipeline

Bijoyesh Mookerjee, MD
*Chief Medical Officer*

# Oncology Clinical R&D Strategy

**Focus on innovation to maximize impact on patients**

- Focus on the highest unmet need
- Innovate to deliver first and best in class medicines
- Continue to deliver new assets and combinations




- Progress therapeutic platforms
- Focused Internal and external collaboration

- Operational excellence
- Strategic decision-making
- Expedited and high-quality clinical trials

- Improve global R&D capabilities
- Prioritize international R&D strategy

# Therapeutic Area Layout

**Clinical value-oriented medicines to provide greater efficacy for cancer patients in China**

## Simcere anti-tumor products approved for market / in clinical trials

| | |
|---|---|
| **Lung cancer** | Endostar® (Endostatin), ENWEIDA® (Envafolimab), Trilaciclib,SIM0201(NTRK), SIM0235(TNFR2) |
| **Breast cancer** | Trilaciclib, SIM0270(SERD BM) |
| **GI tract tumors** | ENWEIDA® (Envafolimab), Docetaxel micelles, Trilaciclib, SIM0235(TNFR2) ,Lenvatinib, Sinofuan®(5-Fu) |
| **Gynecological tumors** | ENWEIDA® (Envafolimab), Sevacizumab,Lenvatinib |

## Estimated incident rates of new cancers (China)




Unit: per 100 thousand people

R. Zheng, et al., Cancer incidence and mortality in China, 2016, Journal of the National Cancer Center, https://doi.org/10.1016/j.jncc.2022.02.002

# Oncology Pipeline Layout

## Maximize existing, and accelerate new medicines and combinations



# Differentiated Targets and Indications

**Providing novel medicines to cancer patients with greater efficacy**

Trilaciclib(CDK4/6): **Short-acting**

Paxalisib(PI3K/mTOR): **BBB permeable**

Envafolimab(PD-L1):**Subcutaneous Injection**

SIM0270(SERD BM): **High BBB permeability**


Trilaciclib: **Bone marrow protection, improved survival**

Endostar®: **Malignant thoracoabdominal effusions**

Paxalisib: **Glioblastoma (GBM)**

**SIM0235(TNFR2):** Novel immunotherapy target

**SIM0272(PRMT5):** Highly selective synthetic lethality

**SIM0237(PD-L1/IL-15v):** Modulating the TME

**SIM0317(RAD51):** New mechanism targeting DDR

**SIM0323(CD80/IL2), SIM0348(TIGIT BiAb), SIM0271(MAT2A)**…

## Key Project Introduction

# Progress in Clinical Trials

# Trilaciclib: a CDK4/6 inhibitor that provides prophylactic bone marrow protection

**Protects hematopoietic stem/progenitor cells (HSPCs) from chemotherapy and enhance the immune system through induction of transient cell cycle arrest**




**S phase-specific chemotherapeutic drugs:** anti-folic acid (methotrexate, pemetrexed), anti-purine (6-MP, 6-TG), anti-pyrimidine (5-FU, capecitabine, azacytidine, gemcitabine, etc.), topoisomerase inhibitors (camptothecin, irinotecan, topotecan, rubitecan, etoposide, teniposide, etc.)

## Prevent multiple adverse events of myelosuppression through multilineage bone marrow protection[1-3]




Mitigate neutropenia, thrombocytopenia and anemia; avoid administration delay and dose reduction




Enhance the activity of anti-tumor T cells and beneficially modulate the tumor microenvironment[4-8]

## Enhance immune response and protect immune function

- Change the proliferation kinetics and composition of T cell subsets in tumors to enhance the number and function of effector T cells
- Enhance T cell activity
- Enhance tumor cell antigen presentation
- Reduce the function of regulatory T cells

1.Weiss J, et al. Ann Oncol. 2019 Aug 27. pii: mdz278; 2.He S, et al. Sci Transl Med. 2017;9:eaal3986 3.Bisi JE, et al. Mol Cancer Ther. 2016;15:783-93; 4.Tan A, et al. Lancet Oncol. 2019 Sep 28 5.Zhang J, et al. Nature. 2018;553:91-95; 6.Jerby-Arnon L, et al. Cell. 2018;175:984-997 7.Goel S, et al. Nature. 2017;548:471-475; 8. Deng J, et al. Cancer Discov. 2018;.216-233. 9 Lai AY, et al. J Immunother Cancer 2020;8:e000847

# Pipeline-in-a-Molecule Opportunity Beyond ES-SCLC Launch




1L CRC data readout in 1Q 2023 expected to include results for myeloprotection and Objective Response Rate (ORR) endpoints
1L TNBC data readout in 2H 2023 expected to include interim results for Overall Survival (OS)
MOA in Neoadjuvant TNBC data readout in 4Q 2022 expected to include results for immune endpoints (e.g., CD8+ / Treg ratio)
1L Bladder Cancer (in combination with an anti-PD-L1) initial data in 4Q 2022 expected to include ORR and myeloprotection endpoints
2L / 3L TNBC (in combination with an ADC) initial data in 4Q 2022 expected to include ORR and myeloprotection endpoints

# Trilaciclib: accelerating the indication process in China

**Only FDA-approved therapy that proactively delivers multilineage myeloprotection to extensive stage SCLC patients being treated with chemotherapy**

**2021/2/12**

On 12 February 2021, FDA fully approved **COSELA™ (Trilaciclib)** for bone marrow protection in ES-SCLC patients, which is **the world's first and only** bone marrow protection therapy that can reduce the incidence of chemotherapy-induced myelosuppression

**2021/11/29**

Submission of Conditional Marketing Authorization Application in China

**2021/12/22**

Included into the priority review species by CDE (130 working days)

**2021/2022**

Recommended by NCCN Guidelines for Small Cell Lung Cancer and Hematopoietic Growth Factors

## TRACES study in China:

**Phase III trial for ES-SCLC treated with 1-3L chemotherapy (N=92)**

- Recruitment completed, total 95 patients enrolled.
- The 1st part: safety lead-in and PK bridging, primary analysis completed, PK and benefit trend consistent with those in overseas countries
- The 2nd part: placebo controlled, primary endpoint met (DSN* in the first cycle).
- Conditional marketing application submitted to China NMPA in November 2021,Priority Review designation granted, expected to be approved in 2022

*DSN; duration of severe neutropenia

## Real-world study in Hainan (N=30)

- The first patient prescribed in June 2021
- Recruitment completed in November 2021
- Complete data analysis within 2022

# Trilaciclib: PRESERVE trials

## For bone marrow protection and survival improvement in CRC and TNBC patients

BARCELONA 2019 ESMO congress

DSN: duration of severe neutropenia; SN: severe neutropenia




| | Group 1 | Group 2 | Group 3 | Group 2+3 |
|---|---|---|---|---|
| ITT | N=34 | N=33 | N=35 | N=68 |
| **mOS** | **12.6** | **20.1** | **17.8** | **20.1** |
| HR | | 0.33 | 0.34 | 0.36 |
| P | | 0.028 | 0.0023 | 0.0015 |




**Trilaciclib showed strong OS improvement**

**in the TNBC randomized controlled phase II trial.**

**In July 2021, TNBC indication was granted Fast Track designation by the FDA.**

## PRESERVE 1 : mCRC (N=296)

China part of global trial

Phase III global clinical trial for bone marrow protection in CRC patients treated with FOLFOXIRI & Bevacizumab (N=296)

- **Primary Endpoint: Duration of severe neutropenia in cycle 1 and occurrence of severe neutropenia during Induction**
- **FPI worldwide: 16 October 2020**
- **FPI in China: 24 September 2021**
- **Enrollment completed in China in March 2022**

## PRESERVE 2 : TNBC ( N=170)

China part of global trial

Phase III global clinical trial of survival improvement in TNBC patients treated with gemcitabine and carbplatin

- **Primary endpoint: Overall Survival**
- **FPI worldwide: 15 April 2021**
- **FPI in China: 7 January 2022**
- **Enrollment ongoing**

Patients randomized to receive gem/carbo chemotherapy only (Group 1) or gem/carbo plus one of two dosing schedules of COSELA: COSELA administered on the day of chemotherapy (Group 2) or COSELA administered the day prior to and the day of chemotherapy (Group 3).

# Endostar® New Indication: malignant thoracoabdominal effusions


Endostar® is a recombinant human endostatin injection approved for first-line treatment of advanced NSCLC in China

Early studies have shown that Endostar® also has a positive therapeutic effect on malignant thoracoabdominal effusions[1]




.Shukui Qin, etc. Chinese Clinical Oncology, 2017

# Endostar® New Indication: COREMAP study

**To address the urgent need of patients with malignant thoracoabdominal effusions**

## COREMAP ： Endostar® for treatment of malignant thoracoabdominal effusions, phase III

CHINA

Intra-pleural injection of recombinant human endostatin/placebo with cisplatin in treatment of malignant thoracoabdominal effusions: a multicenter, randomized, double-blind, controlled phase III trial

- **FPI: 28 July 2021**
- **Recruitment：105 subjects enrolled as of March 30,2022**
- **Interim results analysis expected in H2 2022**

- Among patients with incurable tumors whose expected survival is longer than two weeks, the proportion of abdominal distension caused by ascites and other reasons is as high as 29% (meta analysis).
- According to Frost & Sullivan data, the incidence of intracavitary malignancy reached 707,900 in 2019 and is estimated to increase to 756,900 by 2030.




Shukui Qin, etc. Chinese Clinical Oncology, 2017

# Paxalisib: a potent, oral, selective, BBB permeable small-molecule inhibitor targeting class I PI3K/mTOR




**Glioblastoma (GBM)**
133,000 cases
per annum worldwide


- The main treatment drug is **Temozolomide**
- China's annual market size for GBM is about **2B yuan**
- Temozolomide **almost ineffective for 65%** of the patients (those with unmethylated MGMT status)

## *Paxalisib, a development opportunity of great potential*[2]

- Clinical trials underway in other forms of brain cancer beyond GBM: DIPG, primary CNS lymphoma, brain metastases.
- Potential to combine with chemotherapy, radiotherapy and targeted drugs (e.g,. EGFR inhibitors).
- Potential to target non-brain cancers: Breast cancer, NSCLC, CRC, endometrial cancer, GIST, pancreatic cancer, RCC, TCC, HNSCCs, GBM, leukemia, melanoma, and NHL

1. Corporate deck,2021 2. Porta, Camillo et al. Frontiers in oncology vol. 4 64. 14 Apr. 2014

# Paxalisib: GBM-AGILE

KAZIA THERAPEUTICS

## GBM-AGILE：A trial of Paxalisib in GBM patients

China part of global trial

An international, seamless, phase II/III response adaptative randomized platform trial aimed to evaluate multiple treatment options for newly diagnosed and recurrent glioblastoma (paxalisib group N ≤ 200)

- For the GBM indication, Orphan Drug designation was granted in December 2018 and a Fast Track designation was granted in August 2020 by the FDA
- Favorable safety profile. Most drug-related adverse events were mild (grade 1) or moderate (grade 2), and most of them had either resolved or improved.

➢ **Enrollment ongoing in the US and Canada**

➢ **IND approval in China: 7 December 2021**

A phase II trial of newly diagnosed MGMT-unmethylated glioblastoma showed:




先声药业 Simcere

# Envafolimab

## First PD-L1 Antibody Approved For Subcutaneous Injection




- Envafolimab has a good safety profile as a single agent
- Envafolimab phase II trial for advanced MSI-H/dMMR solid tumor showed it was efficacious[1]. BLA application was submitted to NMPA in December 2020 and approved in November 2021

| 2020 CSCO | | N | ORR | DCR | 12moPFS | 12mo OS |
|---|---|---|---|---|---|---|
| Advanced CRC | Total | 65 | 43.1% | 61.5% | 43.7% | 72.9% |
| | Treatment failure after 3 drugs | 41 | 31.7% | 58.5% | 32.1% | 64.7% |
| | Treatment failure after 2 drugs | 24 | 62.5% | 66.7% | 62.5% | 87.1% |
| Advanced GC | | 18 | 44.4% | 83.3% | 58.0% | 83.3% |
| Other solid tumors | | 20 | 40.0% | 65.0% | 52.6% | 75.0% |
| All subjects | | 103 | 42.7% | 66.0% | 48.5% | 74.6% |

1.2020 CSCO

# Envafolimab and Anti-angiogenic Combinations

## Envafolimab + Sevacizumab

### Phase II trial of Envafolimab combination therapy in solid tumor patients

CHINA

Envafolimab + Sevacizumab: in solid tumors including NSCLC, HCC and CRC

- **Exploration of PD-1+VEGF products**
- **IND approval: 24 August 2021, FPI: 22 December 2021**
- **Continue to explore other possible indications of the combination therapy**
- **Using Simcere Diagnostics TSO500 Kit, benchmarked against FoundationOne® CDx**

# SIM0235： Humanized anti-TNFR2 monoclonal antibody

## New targets for tumor immunity




It can specifically recognize TNFR2[1,2,3] on the cell surface:

- By blocking the activation of TNFR2 by endogenous TNF, it affects TNFR2-mediated immunosuppression and tumor cell proliferation.
- Antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by Fc terminal has a direct killing effect on immunosuppressive cells, including tumor cells expressing TNFR2, regulatory T cells (Tregs) and bone marrow-derived suppressor cells (MDSCs).

**1** **December 2021**
**China IND approved** (1st in same target)

**2** **January 2022**
**US IND approved**

- Exploring the development potential of single agents in solid tumors and hematological tumors
- Actively carry out translational scientific exploration with top international scientists
- March 16, 2022, **FPI (China)**

**TNFR2 Humanized Animal Model: Single Drug Efficacy**




**Animal Model Data: Combination with Anti-PD-L1 Antibody**




1.Williams GS et al., Oncotarget. 2016;2.Vanamee E et al., Trends in Molecular Medicine. 2017;3.Nie Y et al., Sci Scignal. 2018

# SIM0270: BBB permeable, tumor tissue-enriched, BIC oral SERD compound

| Name | R&D company | Clinical phase | Oral | BBB permeability |
|---|---|---|---|---|
| Fulvestrant | AstraZeneca | Approved SERD compound<br>Annual sales exceeding 1 billion US dollars | ⊗ | ⊗ |
| SIM0270 | Simcere | Phase I | ✓ | ✓ |

## CORE ADVANTAGES

- SIM0270 showed superior in vivo and in vitro efficacy to Fulvestrant, comparable to those of GDC-9545, a leading compound in clinical practice.
- SIM0270 showed a significantly better brain-blood ratio than alternative compounds and proved much more effective than Fulvestrant in the brain in situ model; SIM-270 synergistically inhibited tumor growth with CDK4/6 inhibitor Palbociclib in ER+ breast cancer model.
- Phase I clinical trial started in 2021 and phase III expected in 2024




**Significant efficacy in ER+ subcutaneous tumor model in vivo**




**Inhibit ER+ tumor growth combined with Palbociclib in vivo**




**ER+ brain in situ model**



# Milestones 2021-2022

## 2021

| | | |
|---|---|---|
| Trialciclib | Trilaciclib, SCLC bone marrow protection, Phase III | NDA submission |
| Trialciclib | Trilaciclib, CRC bone marrow protection, Phase III | FPI |
| Envafolimab | Envafolimab + Sevacizumab, solid tumor, Phase II | FPI |
| Endostar® | Endostar®, thoracoabdominal effusions, Phase III | FPI |
| Sevacizumab | Sevacizumab, ovarian cancer, Phase III | FPI |
| SIM0201 | NTRK+ solid tumor, Phase I | FPI |
| SIM0235 | TNFR2 antagonist, solid tumor, Phase I | IND approved |
| SIM0270 | SERD, ER+ breast cancer, Phase I | IND approved |
| SIM0395 | Paxalisib, GBM, Phase II/III | IND approved |

= Completed

= Progressing as scheduled

= New molecular entity

= Expansion of indications

## 2022 Goal

| | | |
|---|---|---|
| Trialciclib | Trilaciclib, SCLC bone marrow protection, Phase III | NDA approved |
| Trialciclib | Trilaciclib, CRC bone marrow protection, Phase III | LPI |
| Trialciclib | Trilaciclib, TNBC OS+bone marrow protection, Phase III | FPI; LPI |
| Envafolimab | Envafolimab + BD0801, solid tumor, Phase II | LPI |
| Sevacizumab | Sevacizumab, ovarian cancer, Phase III | LPI, IA |
| SIM0201 | NTRK/ROS1/ALK+, solid tumor, Phase I | LPI |
| SIM0235 | TNFR2 antagonist, solid tumor, Phase I | FPI, FDA IND approved |
| SIM0270 | SERD, ER+ breast cancer, Phase I | FPI |
| SIM0395 | Paxalisib, GBM, Phase II/III | FPI |
| SIM0323 | GI-101/GI-101+PD-1, solid tumor, Phase I | IND approved, FPI |
| SIM0272 | Hematologic malignancy, solid tumor, Phase I | IND approved FPI |

Note: SCLC: small-cell lung cancer, CRC: colorectal cancer, TNBC: triple negative breast cancer, OS: overall survival, ER: estrogen receptor

# Operational Excellence Driving Simcere's Purpose and R&D Vision

New centers initiated in 2021*

**271**

FPI projects in 2021*

**11**

## Leveraging Simcere's strength to provide innovative medicines to patients

Simcere's organizational structure and personnel allows expedited and high quality execution of clinical research.

Effective project launches and clinical trial recruitment together promotes progress to realize Simcere's vision



Patients recruited in 2021*

**1300**

FPI: First patient in
* As of December 31, 2021

# Operational Excellence— New Asset Development

## Clinical trial execution, sets an industry benchmark




The first indication for Trilaciclib submitted for marketing approval in Chinas is for SCLC
*Approved by the US FDA in Feb'21*

NDA submission in
10 months after approval of IND in China

From deal signing, clinical development to submission:
within 15 months

# Globalization to Further Extend Asset Value

## A

**Prioritize international development strategy**

- 6 product candidates targeted for global development
- SIM0235(TNFR2) obtained IND approval from FDA

## B

**In-house development coupled with external partnerships**

- Initiation of global drug development and increasing the capabilities of Simcere

## C

**Establish team in the US**

- Build a clinical R&D team in the US
- Progress to R&D 2.0, by adapting to globalization

## D

**Improve international R&D capabilities**

- Key personnel equipped with international R&D experience
- One Global Team approach to drive international projects

# Providing Today's Patients with Medicines of the Future

**Clinical value-oriented**

**Innovative pipelines**

**Operational Excellence**

**Global R&D Strategy**

# Late-stage Non-oncology Pipeline

Danny Chen , PhD
*SVP*

# Overall Strategy

**Focus on targets and disease of high unmet needs**

## Central Nervous System (CNS)

- Sanbexin®/Sanbexin sublingual indication expansions in China and globally
- Develop novel FIC compounds alone and in combination to further improve treatment outcome in AIS and haemorrhagic stroke
- Explore neurodegenerative diseases and other CNS opportunities

## Autoimmune

- Breakthrough therapy to address the limitations of current treatment
- Focus on rheumatology and dermatology
- Innovative MoA and products

# Summary

## CNS/Autoimmune clinical strategies and highlights – clinical value and differentiation

**Strategy and highlights**

### Focus on patients with enormous unmet medical needs

Avoid hyper-competitive, inefficient involution

### Stay deep-rooted in therapeutic areas of advantage, covering the entire course of the disease

Build a deep moat

### Explore novel targets of high potential

Build high R&D barriers

### Expand potential indications of products

Product life cycle management

# Non-oncology Pipeline

## CNS, Autoimmune, and the disease areas that have significant clinical needs in the future



# Key Project Introduction

## CNS

# CNS Clinical Focus

## Subsegments of nervous system disease

### Neurological drug R&D success rate lower than the average




4:1





### Few domestic players

**Edaravone and Dexborneol Concentrated Solution for injection**

- From 2015, has been the only new medicine for cerebral stroke approved for marketing
- FIC innovative medicine，to meet major clinical needs

### Both China unique and global opportunities




2015-2024E China Central Nervous System Drugs Market[1] (in 100 million yuan)

1 Frost & Sullivan Analysis

# China’s Stroke Treatments Still Have Huge Challenges

## Large Number Patients And Low Thrombolytic Rate

**Number of Discharged Patients with Ischemic and Hemorrhagic Stroke in China 2005-2019[1]**




**About 80% of ischemic stroke patients missed IV thrombolysis treatment window due to hospitalization later than 6h from onset.**

| | | |
|---|---|---|
| Proportion of patients receiving rt-PA within 3 hours of onset[2] | China **18.3%** | US **83.6%** |
| Average thrombolytic rate of AIS in China in 2017[2] | **1.9%** | |
| Ischemic Stroke Patients 5-year Recurrence Rate[3-4] | **41%** | |


1. China Health Statistics Yearbook 2020
2. DOI: 10.3760/cma.j.cn112137-20210416-00914.
3. The lancet global health 10.1016/S2214-109X(20)30069-3
4. China cardiovascular health and disease report 2020

# Sanbexin®: Pivotal Phase III TASTE Study

**48 clinical centers across the country participated in the trial, including ~1200 subjects, and the data were published in mainstream journals**

## Primary efficacy endpoint: Proportion of patients with mRS score ≤ 1 on day 90 of treatment

**Sanbexin 67.18%，Edaravone 58.97%**

*OR:1.42，95%CI:1.12~1.81,* ***P =0.0004***




American Stroke Association

The only journal of the American Stroke Association

# Sanbexin®: TASTE II Ischemic Stroke Reperfusion Study

**Planning to enroll over 1300 subjects, across nearly 80 clinical centers in China**

- A phase IV study to evaluate the efficacy and neurological recovery of Sanbexin combined with early endovascular recanalization therapy in patients with Acute Ischemic Stroke (AIS)
- March 18, 2022： FPI
- Complete 80% enrollment expected in 2022

TASTE-2





The efficacy of newer neuroprotective agent edaravone dexborneol combined with alteplase on AIS

The NA-1 ESCAPE Phase III trial (subgroup analysis results) showed that the application of NA-1 after revascularization can significantly improve neurological function in stroke patients.

*Michael D Hill. Lancet 2020; 395: 878–87*

# Sanbexin®: Hemorrhagic Stroke Indication

## Preclinical study

Animal experiments showed that Sanbexin® could significantly improve the prognosis of cerebral hemorrhage.

- Sanbexin® administration two hours after the onset of collagenase-induced ICH could significantly *relieve the cerebral edema* caused by hemorrhagic stroke.
- Sanbexin® could significantly *improve the permeability* of blood-brain barrier after cerebral hemorrhage.
- Sanbexin® could significantly reduce mNSS and improve motor and sensory dysfunction.




## Clinical development plan

**Phase II exploratory trial: To evaluate the efficacy and safety of different doses of Sanbexin® in the treatment of cerebral hemorrhage**

- The trial will be launched in the end of 2022.
- N≈300

# Sanbexin Sublingual Tablet

**To further expand the effectiveness of Sanbexin in stroke treatment and recovery**






Place the drug or drug preparation under the tongue, and the drug can be directly absorbed into the blood circulation through the sublingual mucosa, so as to exert its curative effect.

| | Phase I in China | Phase III in China |
|---|---|---|
| Register number | CTR20191246 | CTR20210233 |
| Registration date | 24 June 2019 | 24 February 2021 |

# Sanbexin Sublingual Tablet

## Phase III clinical study in the treatment of acute ischemic stroke

CHINA

### Whole course management of stroke (N=914)

- **June 28, 2021, the first case of the subject's delivery**
- **December 31, 2021, achieving the enrollment of 519 subjects, exceeding expectations**
- **March 12, 2022, 783 subjects were enrolled**
- **Interim analysis expected in 2022H1, and complete recruitment of all subjects, and achieve database lock**
- **NDA filing expected in 2023**

**Primary endpoint:** proportion of participants with mRS≤1 on day90 of treatment



# SIM0307:The First Innovative Drug Targeting Aquaporin 4 (AQP4)

- A drug developed based on the scientific achievements of the 2003 Nobel Prize in Chemistry (Aquaporin Physiology)
- China's first and the world's only AQP4 inhibitor that has been approved for clinical development






## Phase I clinical trial in China

- IND approval: April 2021
- FIH: December 2021
- Phase I completion: Q3 2022
- Objective: To evaluate the PK, safety and tolerance of SIM0307 in healthy subjects in Chinese population

# Stroke Pipeline Layout

| Ischemic stroke | Hemorrhagic stroke | Cerebral edema |
|---|---|---|
| Sanbexin®<br>Sanbexin® Sublingual Tablet<br>PSD-95 | Sanbexin® | SIM0307 (AQP4) |

**Early/long-term intervention based on a combination of multiple mechanisms**

- 01 Reduce neuroinflammation
- 02 Remove free radicals, antioxidation
- 03 Prevent cerebral edema
- 04 Improve neuronal survival

# SIM0408: Targeting A Key Catalytic Enzyme in Neurotoxic Aβ Aggregate Formation

**QPCT oral small molecule inhibitor**

Small Molecule Drugs

vivoryon

*SIM0408*

Antibody Drugs

Lilly *Donanemab*

vivoryon *SIM0409*

Antibody Drugs

Biogen *Aducanumab*

**Glutaminyl cyclase (QPCT)** → **Pyroglutamate (pGlu or pE)** → **Precursor oligomer of soluble pE3-42 Aβ** → **Insoluble pE3-42 Aβ plaques that have formed**

- Reduce pE3-42 Aβ pathological plaque formation at the root
- Decreases highly neurotoxic pE3-42 Aβ levels
- Simultaneously inhibits CCL2 activity and improves neuroinflammation

## Clinical Progress and Plan

| | |
|---|---|
| December 20, 2021 | Obtained FDA Fast Track Designation |
| **February 24, 2022** | **Obtained China IND approval** |
| 2022 Plan | Completion of Phase I clinical study and participate in the global Phase II MRCT study |

# Key Project Introduction

## Autoimmune

# Iremod® New Indication: Sjogren's Syndrome

**The efficacy and safety for RA have been verified for over 10 years**


Iremod 艾得辛®

**The world's first and China's only approved iguratimod (IGU) compound**

**The only domestically-developed small-molecule DMARD approved in the past decade**

IIT study: After 24 weeks of treatment with IGU 25mg bid, the ESSDAI score, hyperglobulinemia and ESR of the patients were significantly lower than those at baseline




Lizhanguo team. EULAR. Ann Rheum Dis, 2019, 78 (suppl 2): A1696 (No.AB0465)
https://doi.org/10.3389/fphar.2021.621208

# Iremod® New Indication: Sjogren's Syndrome





Recurrent bronchitis


Joint pain


Liver dysfunction


Digestive problems


Muscle pain


Vaginal dryness


Nervous system disorders

Population prevalence in China

**0.33%~0.77%**

Prevalence of the elderly

**3%~4%**

The pathogenesis has not been elucidated

Lack of effective clinical drugs

In April 2020, Iremod entered the "China Standard for the Diagnosis and Treatment of Primary Sjögren's Syndrome"

## Clinical Progress and Plan

| | |
|---|---|
| April 28, 2021 | FPI |
| December 31, 2021 | 129 subjects recruited |
| **January 20, 2022** | **Completed the recruitment of all 144 subjects and LPLV will achieve by the end of April** |
| 2022 plan | Completion of Phase II clinical results readout and initiation of Phase III clinical studies |

# LNK01001： Selective Jak1 Inhibitor

March 18, 2022, Simcere entered into a collaboration agreement with Lynk Pharmaceuticals, to obtain the exclusive commercialization interest of LNK01001 for rheumatoid arthritis (RA) and Ankylosing spondylitis (AS) indications in China. Lynk Pharmaceuticals will be responsible for the clinical development of LNK01001.

LYNK PHARMACEUTICALS

RA AS

## Phase 1 PK and PD summary:

- **SAD:** PK parameters increase proportionally in the range of 6 mg to 84 mg along with the dose.Exposure in vivo to LNK01001 AUC and Cmax are linearly kinetic.
- **MAD:** AUCs with multiple administrations on D1 & D7: basically consistent; basically, no accumulation in the body
- **FE:** AUC shows no significant change with fasting or eating state; postprandial administration has no significant effect on the metabolism and elimination of LNK01001; elimination of half-life period(T1/2) Not change significantly with fasting or eating
- **PD:** good Pharmacokinetic and Pharmacodynamic relationship (pSTAT Inhibition assay)

## Phase I studies in healthy subjects demonstrats good safety and tolerability

- No TEAE above >2 or higher during the trial;
- No SAE;
- No death-causing TEAE;
- No TEAE leading to discontinuation;
- No dose-related incidence of adverse events

# Milestones Expected in 2022

### Iremod® (Sjogren's syndrome)

Iremod® Tablet, primary Sjogren's syndrome, phase II
Result summary of phase II; Regulatory communication before phase III

### Sanbexin®(Cerebral hemorrhage)

Hemorrhagic stroke as a newly added indication of Sanbexin®, phase II
FPI

### Sanbexin®(Reperfusion)

Sanbexin® combined with reperfusion for AIS treatment, phase IV
Achieve the enrollment goal

### SIM0307（AQP4）

Acute severe ischemic stroke complicated with cerebral edema, phase I ,CSR

### SIM0417(3CL)

Orally Administered SSD8432, COVID-19 Treatment, phase I & phase II/III
Phase I, CSR
Phase II/III, FPI

### SIM0408(QPCT)

Varoglutamstat, AD, phase IIb in Europe (international multicenter)
FPI

### Sanbexin Sublingual Tablet

Y-2 for AIS treatment, phase III
LPLV, DBL

### SIM0335

CKBA for treatment of mild to moderate psoriasis, phase II
FPI, LPI

### SIM0278

IL-2 for treatment of systemic lupus Erythematosus
FDA IND

# Strengthening BD, M&A and Investments within a Global Strategy

Kevin Oliver , PhD
*SVP, Global Head of BD&L*

# Simcere's BD/M&A Team has high credibility, is diverse and has a deep reputation in the industry

**30**
FTEs

**250+**
transactions executed, alliances managed, acquisitions integrated collective experience

**2018、2019、2020**
Association of Strategic Alliance Professional (ASAP) Excellence Awards

## TRANSACTIONS

**Kevin Oliver**
SVP Global Head of BD&L

**Yuehua Cong**
ED Head of BD&L EU

**Yves McMullen**
Head of US Transactions and Global Invest.

**Gaobo Zhou.**
CIO, Head of BD&L AP

**Michael Bayewitch**
ED, US AP Transactions

## LEGAL

**Ian Liu**
Head of Legal & Gov't Affairs, US EU

## AM

**Mark Coflin**
VP Global Alliance Management

## S&E

**Catherine Abbadie**
Global Head of CNS S&E

**Matthias Höss**
Global Head of Autoimmune S&E

**Markus Decker,**
Global Head, Oncology S&E

# BD is geographically established to become ‘Partner of Choice’




**Search & Evaluation (S&E)**

Screen / DD

**Transactions**

Negotiate

**Alliance & Integration Management (AM)**

Manage

**Post-Investment Management (PIM)**

Transact & Manage

# Global expansion, centered in Boston, will focus on six key, global operational strategies



# People, Integrity, Trust and proven Capabilities are critical to being ‘Partner of Choice’



# Simcere values its existing 35+ alliances and LP positions

思路迪医药 3D Medicines 康宁杰瑞 ALPHAMAB ONCOLOGY

Collaboration to develop and commercializ Enweida® , world's first SC PD-L1 antibody

G1 THERAPEUTICS

Collaborate to introduce COSELA™(Trilaciclib),a first-in-class cancer therapy, in China

KAZIA THERAPEUTICS

Co-development of Paxalisib ,a novel therapy of glioblastoma

LYNK PHARMACEUTICALS

Commercialization of LNK01001, a highly selective Janus kinase 1 (JAK1) inhibitor

vivoryon therapeutics

Collaborate to develop and commercialize Varoglutamstat,a novel molecule for Alzheimer's disease

ND NeuronDawn

Collaborate to develop Sanbexin® (Edaravone and Dexborneol Concentrated Solution for Injection)

Avilex pharma

Collaboration on AVLX-144,an innovative drug for stroke

aeromics Inc

Partner with a Nobel laureate as the founder of science
Co-development of novel therapy for cerebral edema in China

Bristol Myers Squibb™

Co-development of Orencia® (Abatacept), a blockbuster drug for RA in China

Daiichi-Sankyo

Strategic partner
Exclusive commercialization of Olmetec Plus® ( Olmesartan medoxomil, Hydrochlorothiazide) in China

JW Pharmaceutical

Collaborate withthe second largest pharmaceutical company in Korea to develop new drug for gout in China

SIMM 中国科学院上海药物研究所 Shanghai Institute of Materia Medica. Chinese Academy of Sciences

Partnership to develop novel antiviral drugs for COVID-19

MPM

GT HEALTHCARE CAPITAL PARTNERS

LSP CONNECTING INVESTORS TO INVENTORS

CORMORANT ASSET

# Strategically driven BD: In-licensing interests in Oncology

## Small molecule and biologics

Focus on high unmet need indications that are TOP10 prevalent tumor types in China

Focus on assets with clinical PoC in relevant indications (preferred)

Earlier stage assets (≥ late preclinical) with innovative mechanisms need to have potential to deliver highly differentiated patient benefit – Best-in-class and/or First-in-class

Modality agnostic

Flexible partnership models (In-licensing/Co-dev, R&D collaborations, JV & Equity Investment, M&A)

## Innovative modalities

High-throughput structure-based drug screening (Challenging Targets)

Novel drug targets with First-in-class and/or Best-in-class potential

Novel drug classes/modalities (RNA therapeutics, Tetra-specific IgG mAb, gastrobodies,)

Novel ex-vivo functional screening platforms (Novel types of SL interactions)

Novel platform capability partnering with academia – relationships that lead to global licensing rights and an engine to feed the pipeline

Late / commercial stage M&A

# Strategically-driven BD: In-licensing interests in CNS and Autoimmune

## General

Focus on high unmet medical need in China

Later stage assets with clinical PoC in relevant indications

Earlier stage assets (≥ late preclinical) with innovative mechanisms need to have potential to deliver highly differentiated patient benefit

Flexible partnership models (In-licensing/Co-dev, R&D collaborations, JV & Equity Investment opportunities)

## CNS

Neurology: Focus on Stroke

Neurodegeneration: Parkinson’s, Alzheimer’s

Pain, Sleep

Psychiatry: Depression, Anxiety, Schizophrenia

## Autoimmune

Indications with immune-mediated pathology and high unmet need in China

Current focus on rheumatology and dermatology

# Exclusive License Agreement for Trilaciclib in Greater China


**2020**

**2020.08.03**
Established collabration

**2020.11.18**(SCLC)
IND for leading indication submitted to NMPA

**2021**

**2021.01.19**
IND for leading indication approved

**2021.02.02**
US FDA Approval

**2021.04.13**(CRC)
**2021.06.11** (TNBC)
Later indications to join MRCT IND approval

**2021.11.29**
(SCLC)
NDA submission

**2022**

**2022.H2** (SCLC)
NPMA conditional approval

SCLC: FPI-2021.05.25; LPI-2021.12.1
mCRC: FPI-2021.09.24; LPI-2022.04
TNBC: FPI-2022.01.07; LPI-2022.06

An investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.

Received FDA Breakthrough Designation for patients with Small Cell Lung Cancer (SCLC).


BioWorld™

**Simcere licenses CDK4/6 inhibitor from G1 Therapeutics in $170M deal**

By Elise Mak Aug. 4, 2020


Forbes Subscribe Sign In

**China's Simcere Pharmaceutical Advances At Home After Exit From NYSE**

# Exclusive License Agreement for small molecule, PQ912, and biologic in Greater China




Phase 2 N3pE Amyloid-Targeting Medicines to Treat Alzheimer's Disease.

Best efficacy among available clinical opportunities
Huge potential upside with mild cognitive impairment patients



# 3DMed Alphamab Exclusive License Agreement for Envafolimab in Mainland China

3DMed 康宁杰瑞 ALPHAMAB ONCOLOGY

先声药业 Simcere

2020

2020.03.30
Established collabration

2020.12.17
BLA submission to NMPA

2021

2021.11.24
BLA approval

2021.12.3
First prescription

First subcutaneous injection in PD-L1 category around the world

First PD-L1 developed by Chinese in China


全球首个PD-L1皮下注射制剂获批！先声药业携手思路迪医药、康宁杰瑞推出肿瘤免疫治疗创新药物

先声药业 2021-11-26 11:17

收录于话题
#恩沃利单抗 20 #研发动态 53

2021年11月26日，先声药业(2096.HK)与思路迪医药、康宁杰瑞生物制药(9966.HK)共同宣布，三方战略合作的PD-L1单域抗体恩维达®(恩沃利单抗注射液)正式获得国家药品监督管理局(NMPA)批准上市(批准文号：国药准字S20210046)，成为全球首个且目前唯一获准上市的皮下注射PD-L1抗体药物。

# Simcere as Partner of Choice in China… with global ambitions

World class manufacturing

Comprehensive portfolio in key therapeutic areas of focus

In house clinical and diagnostic capabilities to ensure success along the China drug development pathway

Regulatory expertise navigating the development and approval path for your products and enabling the acceleration of global product development

Experienced executive management with decades of experience both within China and globally; US-based leadership

Experienced BD and M&A Team with over 250 transactions executed and alliances managed with proven experience in ensuring successful partnering outcomes

Seasoned commercialization team with proven track record of sales in China

# Q & A

## ATTENDEES

**HOST :** Jason Bao
*Secretary of the Board*

Dr.Tang

Mr.Zhou

Dr. Mookerjee

Dr. Chen

Dr. Oliver

Andrew Zhu
*SVP*

SIMCERE PHARMACEUTICAL GROUP LIMITED

# 2022 R&D DAY

*STOCK CODE: 2096.HK*


**IR CONTACTS**

Tel: +86(25)8556 6366 Email: ir@simcere.com

Postal Address: Board Office, Simcere Pharmaceutical Group Limited 699-18 Xuanwu Avenue, Xuanwu District, Nanjing, Jiangsu, PRC

WeChat: Jason Bao